A new vaccination strategy is urgently needed for improved control of the global tuberculosis (TB) epidemic. Using a mouse aerosol Mycobacterium tuberculosis challenge model, we investigated the protective efficacy of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG (ΔmmaA4BCG) formulated in dimethyl dioctadecyl ammonium bromide (DDA) – D(+) trehalose 6,6 dibenenate (TDB) (DDA/TDB) adjuvant. In previous studies, deletion of the mmaA4 gene was shown to reduce the suppression of IL-12 production often seen after mycobacterial infections. While the non-adjuvanted ΔmmaA4BCG strain did not protect mice substantially better than conventional BCG against a tuberculous challenge in four protection experiments, the protective responses induced by the ΔmmaA4BCG vaccine formulated in DDA/TDB adjuvant was consistently increased relative to nonadjuvanted BCG controls. Furthermore, the ΔmmaA4BCG-DDA/TDB vaccine induced significantly higher frequencies of multifunctional (MFT) CD4 T cells expressing both IFNγ and TNFα (double positive) or IFNγ, TNFα and IL-2 (triple positive) than CD4 T cells derived from mice vaccinated with BCG. These MFT cells were characterized by having higher IFNγ and TNFα median fluorescence intensity (MFI) values than monofunctional CD4 T cells. Interestingly, both BCG/adjuvant and ΔmmaA4BCG/adjuvant formulations induced significantly higher frequencies of CD4 T cells expressing TNFα and IL-2 than nonadjuvanted BCG or ΔmmaA4BCG vaccines indicating that BCG/adjuvant mixtures may be more effective at inducing central memory T cells. Importantly, when either conventional BCG or the mutant were formulated in adjuvant and administered to SCID mice or immunocompromised mice depleted of IFNγ, significantly lower vaccine-derived mycobacterial CFU were detected relative to immunodeficient mice injected with non-adjuvanted BCG. Overall, these data suggest that immunization with the ΔmmaA4BCG/adjuvant formulation may be an effective, safe, and relatively inexpensive alternative to vaccination with conventional BCG.
References
[1]
World Health Organization website. Available: http://whqlibdoc.who.int/publications/20？09/9789241563802_eng.pdf. Accessed 2012 Feb.
[2]
Shenol S, Friedland G (2009) Extensively drug-resistant tuberculosis: A new face to an old pathogen. Ann Rev Med 60: 307–320.
[3]
Jassal MS, Bishai WR (2010) Epidemiology and challenges to the elimination of global tuberculosis. Clin Infect Dis 50: S156–S164.
[4]
Rodrigues LC, Diwan VK, Wheeler JG (1993) Protective effect of BCG against tubercular meningitis and military tuberculosis: a meta-analysis. Int j Epidemiol 22: 1154–1158.
[5]
Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis: A meta-analysis of the published literature. JAMA 271: 698–702.
[6]
Soysal A, Millington KA, Bakir M, Aslan Y, Deeks JJ, et al. (2005) Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366: 1443–1451.
[7]
Pulickal AS, Fernandez GVJ (2007) Comparison of the prevalence of tuberculosis infection in BCG vaccinated versus non-vaccinated school age children. Indian Pediatrics 44: 344–347.
[8]
Eriksen J, Chow JY, Mellis V, Whipp B, Walters S, et al. (2010) Protective effect of BCG vaccination in a nursery outbreak in 2009: time to reconsider the vaccination threshold. Thorax 65: 1067–1071.
[9]
Fine PE, Rodrigues LC (1990) Modern vaccines: Mycobacterial diseases. Lancet 335: 1016–1020.
[10]
Fine PE (2001) BCG: the challenge continues. Scand J Infect Dis 33: 243–245.
[11]
Beresford B, Sadoff JC (2010) Update on research and development pipeline: tuberculosis vaccines. Clin Infect Diseases 50: S178–S183.
[12]
Parida SK, Kaufmann SH (2010) Novel tuberculosis vaccines on the horizon. Curr Opin Immunol 22: 374–384.
[13]
Aldwell FE, Brandt L, Fitzpatrick C, Orme IM (2005) Mice fed lipid-encapsulated Mycobacterium bovis BCG are protected against aerosol challenge with Mycobacterium tuberculosis. Infect Immun 73: 1903–1905.
[14]
Buddle B, Aldwell FE, Skinner MA, de Lisle GW, Denis M (2005) Effect of oral vaccination of cattle with lipid-formulated BCG on immune responses and protection against bovine tuberculosis. Vaccine 23: 3581–3589.
[15]
Aldwell FE, Cross ML, Fitzpatrick CE, Lambeth MR, de Lisle GW, et al. (2006) Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis. Vaccine 24: 2071–2076.
[16]
Dietrich J, Billeskov R, Doherty TM, Andersen P (2007) Synergistic effect of Bacillus Calmette Guerin and a tuberculosis subunit vaccine in cationic liposomes: Increased immunogenicity and protection. J Immunol 178: 3721–3730.
[17]
Clark SC, Cross ML, Nadian A, Vipond J, Court P, et al. (2008) Oral vaccination of guinea pigs with Mycobacterium bovis Bacillus Calmette-Guerin vaccine in a lipid matrix protects against aerosol infection with virulent M. bovis. Infect Immun 76: 3771–3776.
[18]
Corner LAL, Costello E, O'Meara D, Lesellier , Aldwell FE, et al. (2010) Oral vaccination of badgers (Meles meles) with BCG and protective immunity against endobronchial challenge with Mycobacterium bovis. Vaccine 28: 6265–6272.
[19]
Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, et al. (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nature Med 9: 533–539.
[20]
Grode L, Seller P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, et al. (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacilli Calmette Guerin mutants that secrete listeriolysin. J Clin Invest 115: 2472–2479.
[21]
Dao DN, Sweeney K, Hsu T, Gurcha SS, Nascimento IP, et al. (2008) Mycolic acid modification by the mmaA4 gene of M. tuberculosis modulates IL-12 production. PLOS Pathogens 4: 1–14.
[22]
Ottenhoff T, Doherty TM, van Dissel JT, Bang P, Lingnau K, et al. (2010) A new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis- specific Th1-cell like responses. Human Vaccine 6: 1007–1015.
[23]
Derrick SC, Yabe IM, Yang A, Morris SL (2011) Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 29: 2902–2909.
[24]
Flynn J, Chan J (2001) Immunology of tuberculosis. Ann Rev Immunol 19: 93–129.
[25]
Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nature Medicine 13: 843–850.
[26]
Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR (2007) Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 81: 8468–8476.
[27]
van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P (2000) Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 12: 3689–3698.
[28]
Hesseling AC, Marais BJ, Schaaf HS, Fine PE, Godfrey-Faucett P, et al. (2007) The risk of disseminated Bacille Calmette-Guerin (BCG) diseases in HIV-infected children. Vaccine 25: 14–18.
[29]
Hesseling AC, Cotton MF, von Reyn CF, Graham SM, Gle RP, et al. (2008) Consensus statement on the revised World Health Organization recommendations for BCG vaccination of HIV-infected infants. Int J Tuber Lung Dis 12: 1376–1378.
[30]
Tsukamoto T, Takeda A, Yamamoto T, Kaweda M, Matano T (2009) Impact of cytotoxic-T-lymphocyte memory induction without virus-specific CD4+ T-cell help on control of a simian immunodeficiency virus challenge in rhesus macaques. J Virol 83: 9339–9346.
[31]
Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P (2007) Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol 81: 12071–12076.
[32]
Lindenstrom T, Agger EM, Korshohn KS, Darrah PA, Aagaard C (2009) Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 182: 8047–8055.
[33]
Orme IM (2010) The Achilles heel of BCG. Tuberculosis 90: 329–332.
[34]
Christensen D, Agger EM, Andreasen LV, Kirby D, Andersen P (2009) Liposome-based cationic adjuvant formulations (CAF): Past, present, and future. J Liposome Res 19: 2–11.
[35]
Henricksen-Lacy M, Bramwell VW, Christensen D, Agger EM, Andersen P, et al. (2009) Liposomes based on dimethyldioctadecylamonium promote a depot effect and enhance immunogenicity of soluble antigen. J Controlled Release 142: 180–186.
[36]
Kamath A, Woodworth JS, Behar SM (2006) Antigen-specific CD8+ T cells and the development of central memory during Mycobacterium tuberculosis infection. J Immunol 177: 6361–6369.
[37]
UNAIDS website. Global report (2008) Available: www.unaids.org/en//2008reportontheglobal？aidsepidemic/. Accessed 2012 Feb.
[38]
Haterill M, Mahomed H, Hanekom W (2010) Novel vaccine prime and selective BCG boost: A new tuberculosis vaccine strategy for infants of HIV-infected mothers. Vaccine 28: 4550–4552.
